These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 20139035)

  • 41. Anti-IgE as a mast cell-stabilizing therapeutic agent.
    Chang TW; Shiung YY
    J Allergy Clin Immunol; 2006 Jun; 117(6):1203-12; quiz 1213. PubMed ID: 16750976
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Bicistronic expression plasmid encoding allergen and anti-IgE single chain variable fragment antibody as a novel DNA vaccine for allergy therapy and prevention.
    Bandbon Balenga NA; Thalhamer J; Weiss R
    Med Hypotheses; 2006; 67(1):71-4. PubMed ID: 16513289
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Engineering the Fab fragment of the anti-IgE omalizumab to prevent Fab crystallization and permit IgE-Fc complex crystallization.
    Mitropoulou AN; Ceska T; Heads JT; Beavil AJ; Henry AJ; McDonnell JM; Sutton BJ; Davies AM
    Acta Crystallogr F Struct Biol Commun; 2020 Mar; 76(Pt 3):116-129. PubMed ID: 32133997
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Current Strategies to Inhibit High Affinity FcεRI-Mediated Signaling for the Treatment of Allergic Disease.
    Gomez G
    Front Immunol; 2019; 10():175. PubMed ID: 30792720
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Double-blind placebo-controlled trial of the effect of omalizumab on basophils in chronic urticaria patients.
    Jörg L; Pecaric-Petkovic T; Reichenbach S; Coslovsky M; Stalder O; Pichler W; Hausmann O
    Clin Exp Allergy; 2018 Feb; 48(2):196-204. PubMed ID: 29164723
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Improved FcγRIIb targeting functionally translates into enhanced inhibition of basophil activation.
    Buschor P; Eggel A; Zellweger F; Stadler BM; Vogel M
    Int Arch Allergy Immunol; 2014; 163(3):206-14. PubMed ID: 24557487
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcεRI-positive cells in the skin.
    Metz M; Staubach P; Bauer A; Brehler R; Gericke J; Kangas M; Ashton-Chess J; Jarvis P; Georgiou P; Canvin J; Hillenbrand R; Erpenbeck VJ; Maurer M
    Theranostics; 2017; 7(5):1266-1276. PubMed ID: 28435464
    [No Abstract]   [Full Text] [Related]  

  • 48. A fluorescent biosensor reveals conformational changes in human immunoglobulin E Fc: implications for mechanisms of receptor binding, inhibition, and allergen recognition.
    Hunt J; Keeble AH; Dale RE; Corbett MK; Beavil RL; Levitt J; Swann MJ; Suhling K; Ameer-Beg S; Sutton BJ; Beavil AJ
    J Biol Chem; 2012 May; 287(21):17459-17470. PubMed ID: 22442150
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A molecular model of type I allergy: identification and characterization of a nonanaphylactic anti-human IgE antibody fragment that blocks the IgE-FcepsilonRI interaction and reacts with receptor-bound IgE.
    Laffer S; Hogbom E; Roux KH; Sperr WR; Valent P; Bankl HC; Vangelista L; Kricek F; Kraft D; Grönlund H; Valenta R
    J Allergy Clin Immunol; 2001 Sep; 108(3):409-16. PubMed ID: 11544461
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Use of Engineered Nanoparticles (ENPs) for the Study of High-Affinity IgE FcεRI Receptor Engagement and Rat Basophilic Leukemia (RBL) Cell Degranulation.
    Alelwani W; Alharbi RA; Wan D; Vllasaliu D; Falcone FH; Stolnik S
    Methods Mol Biol; 2020; 2163():171-180. PubMed ID: 32766975
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Improved FcεRI-Mediated CD203c Basophil Responsiveness Reflects Rapid Responses to Omalizumab in Chronic Spontaneous Urticaria.
    Oda Y; Fukunaga A; Washio K; Imamura S; Mizuno M; Hatakeyama M; Ogura K; Nishigori C
    J Allergy Clin Immunol Pract; 2021 Mar; 9(3):1166-1176.e8. PubMed ID: 32898709
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Development and characterization of a novel anti-IgE monoclonal antibody.
    Qian W; Zhang X; Li B; Zhang D; Tong Q; Chen L; Zheng L; Kou G; Wang H; Hou S; Guo Y
    Biochem Biophys Res Commun; 2010 May; 395(4):547-52. PubMed ID: 20394728
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Roles for the High Affinity IgE Receptor, FcεRI, of Human Basophils in the Pathogenesis and Therapy of Allergic Asthma: Disease Promotion, Protection or Both?
    Youssef LA; Schuyler M; Wilson BS; Oliver JM
    Open Allergy J; 2010; 3():91-101. PubMed ID: 25018787
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Structural basis of omalizumab therapy and omalizumab-mediated IgE exchange.
    Pennington LF; Tarchevskaya S; Brigger D; Sathiyamoorthy K; Graham MT; Nadeau KC; Eggel A; Jardetzky TS
    Nat Commun; 2016 May; 7():11610. PubMed ID: 27194387
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Age-dependent increase of IgE-binding and FcepsilonRI expression on circulating basophils in children.
    Wada T; Toma T; Shimura S; Kudo M; Kasahara Y; Koizumi S; Ra C; Seki H; Yachie A
    Pediatr Res; 1999 Nov; 46(5):603-7. PubMed ID: 10541325
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Development of an in vitro model system for studying the interaction of Equus caballus IgE with its high-affinity receptor FcɛRI.
    Sabban S; Ye H; Helm B
    Vet Immunol Immunopathol; 2013 May; 153(1-2):10-6. PubMed ID: 23485176
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Tracing Human IgE B Cell Antigen Receptor-Bearing Cells With a Monoclonal Anti-Human IgE Antibody That Specifically Recognizes Non-Receptor-Bound IgE.
    Zghaebi M; Byazrova M; Flicker S; Villazala-Merino S; Campion NJ; Stanek V; Tu A; Breiteneder H; Filatov A; Khaitov M; Niederberger-Leppin V; Eckl-Dorna J; Valenta R
    Front Immunol; 2021; 12():803236. PubMed ID: 34987522
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Structural and Physical Basis for Anti-IgE Therapy.
    Wright JD; Chu HM; Huang CH; Ma C; Chang TW; Lim C
    Sci Rep; 2015 Jun; 5():11581. PubMed ID: 26113483
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab.
    Gasser P; Tarchevskaya SS; Guntern P; Brigger D; Ruppli R; Zbären N; Kleinboelting S; Heusser C; Jardetzky TS; Eggel A
    Nat Commun; 2020 Jan; 11(1):165. PubMed ID: 31913280
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Quantitation of serum IgE by using chimeras of human IgE receptor and avian immunoglobulin domains.
    Braren I; Greunke K; Pilette C; Mempel M; Grunwald T; Bredehorst R; Ring J; Spillner E; Ollert M
    Anal Biochem; 2011 May; 412(2):134-40. PubMed ID: 21146489
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.